Prognostic Factors According to the Treatment Schedule in Malignant Pleural Mesothelioma
Prognostic Factors According to the Treatment Schedule in Malignant Pleural Mesothelioma
复制标题
DOI：
10.1097/jto.0b013e3181ba2033
复制
发表时间：
2009-11-01
影响因子：
20.4
通讯作者：
Cadirci, Omer
中科院分区：
文献类型：
--
作者：
Ak, Guntulu;Metintas, Selma;Cadirci, Omer
目的：在这项研究中，我们的目的是探讨影响恶性胸膜间皮瘤（MPM）患者的生存的因素，根据他们的治疗方案，包括最好的支持治疗，化疗和多模式therapy.Methods：我们评估了235例MPM患者。根据治疗方案，患者被分为三组：最佳支持护理组、化疗组和综合治疗组。通过单变量和多变量分析确定所有患者和三组的预后因素。然而，作为一个预后因素的治疗方案的有效性没有在这项研究中进行评估。结果：调整治疗后的考克斯模型，Kamofsky性能状态（KPS）500 IU（-1），非上皮亚型，3至4期疾病的多变量分析确定为所有患者的不利预后因素。KPS 500 IU（-1），一种非上皮亚型和3 - 4期疾病与最佳支持治疗组的预后不良相关。化疗组的单一不良预后因素是KPS
Objectives: In this study, we aimed to investigate the factors affecting the survival of patients with malignant pleural mesothelioma (MPM) according to their treatment schedules, including those treated with best supportive care, chemotherapy, and multimodality therapy.Methods: We evaluated 235 patients with MPM. The patients were classified into three groups according to their treatment schedules: the best supportive care group, the chemotherapy group, and the multimodality therapy group. Prognostic factors were determined for all patients and for the three groups by univariate and multivariate analyses. However, the effectiveness of treatment schedules as a prognostic factor was not evaluated in this study.Results: After adjusting for therapy in a Cox model, a Kamofsky Performance Status (KPS) 500 IU(-1), a nonepithelial subtype, and stage 3 to 4 disease were determined by multivariate analyses to be unfavorable prognostic factors for all the patients. A KPS 500 IU(-1), a nonepithelial subtype, and stage 3 to 4 disease were associated with a poor prognosis for the best supportive care group. The single unfavorable prognostic factor for the chemotherapy group was a KPS